Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tianqi Sun

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Journal of Medicinal Chemistry|April 5, 2025
Structure-Based Design and Optimization Lead to the Identification of a Novel Potent sEH Inhibitor with PPARγ Partial Agonist Activity against Inflammatory and Metabolic-Related DiseasesRuolin Cao, Maoying Zhang, Minggang Qi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2021
Early Interdisciplinary Supportive Care in Patients With Previously Untreated Metastatic Esophagogastric Cancer: A Phase III Randomized Controlled TrialZhihao Lu, Yu Fang, Chang Liu, et al.
Gynecologic Oncology|November 23, 2024
The prognostic value of tumor-informed minimal residual disease detection using circulating tumor DNA in first-line treatment of ovarian cancerTong Shu, Yiming Liang, Siwen Zhang, et al.
Signal Transduction and Targeted Therapy|June 27, 2024
Clinical efficacy and identification of factors confer resistance to afatinib (tyrosine kinase inhibitor) in EGFR-overexpressing esophageal squamous cell carcinomaYanni Wang, Chang Liu, Huan Chen, et al.
NPJ Precision Oncology|May 31, 2023
HRD effects on first-line adjuvant chemotherapy and PARPi maintenance therapy in Chinese ovarian cancer patientsLei Li, Yu Gu, Mengpei Zhang, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Journal of Medicinal Chemistry|April 5, 2025
Structure-Based Design and Optimization Lead to the Identification of a Novel Potent sEH Inhibitor with PPARγ Partial Agonist Activity against Inflammatory and Metabolic-Related DiseasesRuolin Cao, Maoying Zhang, Minggang Qi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2021
Early Interdisciplinary Supportive Care in Patients With Previously Untreated Metastatic Esophagogastric Cancer: A Phase III Randomized Controlled TrialZhihao Lu, Yu Fang, Chang Liu, et al.
Gynecologic Oncology|November 23, 2024
The prognostic value of tumor-informed minimal residual disease detection using circulating tumor DNA in first-line treatment of ovarian cancerTong Shu, Yiming Liang, Siwen Zhang, et al.
Signal Transduction and Targeted Therapy|June 27, 2024
Clinical efficacy and identification of factors confer resistance to afatinib (tyrosine kinase inhibitor) in EGFR-overexpressing esophageal squamous cell carcinomaYanni Wang, Chang Liu, Huan Chen, et al.
NPJ Precision Oncology|May 31, 2023
HRD effects on first-line adjuvant chemotherapy and PARPi maintenance therapy in Chinese ovarian cancer patientsLei Li, Yu Gu, Mengpei Zhang, et al.
Pageof 3